I like this stock too... Health Discovery Corporation (OTCBB: HDVY) today announced that it has entered into an agreement with Abbott (NYSE: ABT) to commercialize HDC’s new molecular diagnostics gene-based tests for clinically significant prostate cancer. Abbott has acquired co-exclusive clinical laboratory rights and exclusive in vitro diagnostic rights for commercialization of HDC’s tissue-based prostate cancer test as well as HDC’s urine-based prostate cancer test.
“We are very pleased to partner with Abbott on commercialization of these exciting new molecular diagnostic tests for prostate cancer,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “Abbott is an innovative leader in the fast paced, high growth medical technology space serving customers around the world.”
About Health Discovery Corporation
Savannah-based Health Discovery Corporation (OTCBB: HDVY)) is uniquely positioned in the field of pattern recognition technology. Through the application of its patent protected technology, HDC is a leader in SVM-based molecular diagnostic and prognostic test development in genomics and proteomics, as well as, digital image analysis in pathology and radiology. The Company's SVM and FGM pattern recognition tools have significant application potential in other sizable commercial markets such as oil exploration, financial markets, Internet search and spam, homeland security, and other areas where analysis of large volumes of complex data is required.
This news release contains "forward-looking statements" within the meaning of Section 27a of the Securities Acts of 1933 and Section 21E of the Securities Exchange Act of 1934. Although the management team of HDC believes that the expectations reflected in such forward-looking statements are reasonable, they can give no assurance that such expectations will prove correct.
Contact
Health Discovery Corporation
Stephen D. Barnhill, M.D.
1-912-443-1987
sbarnhill@healthdiscoverycorp.com
AI
